儿童低级别胶质瘤的青春期发育与激素调控:回顾性队列研究
该单中心回顾性队列纳入2015—2025年301例组织学确诊的儿童低级别胶质瘤(pLGG),评估青春期发育与中枢性性早熟(CPP)对肿瘤行为的影响。37%患者Tanner分期>3,6%符合CPP标准,且CPP患儿肿瘤多累及间脑或下丘脑-视路。CPP患者中接受GnRH类似物者无进展生存期显著优于未治疗者(p=0.00038)。
要点
- CPP患儿肿瘤多位于下丘脑-视路区域,需关注青春期发育监测。
- CPP患者GnRH类似物治疗与更长PFS相关(60个月PFS 78% vs 25%)。
- 停用GnRH治疗后肿瘤进展常与青春期重新激活同时出现。
核心结论
- 青春期发育与CPP和儿童低级别胶质瘤相关,GnRH类似物激素抑制与CPP患儿PFS延长相关。
- 内分泌信号可能对pLGG具有调控作用,需前瞻性研究进一步明确。
研究设计与样本
- 单中心回顾性队列研究,纳入2015—2025年301例组织学确诊的儿童低级别胶质瘤患儿。
- 收集临床、影像、内分泌、组织病理和分子信息,采用Tanner分期评估青春期状态。
主要发现
- 112例(37%)观察到青春期发育提前(Tanner分期>3),18例(6%)符合CPP标准。
- CPP患儿中,GnRH类似物治疗组(n=13)PFS显著长于未治疗组(n=5)(p=0.00038),60个月PFS分别为78%与25%。
- 与无CPP的年龄匹配儿童相比,GnRH治疗显示PFS延长趋势但无统计学显著性(p=0.10)。
- 停用GnRH治疗后肿瘤进展常与青春期重新激活同时出现。
关键数值与推荐
- CPP定义采用标准临床和激素标准。
- 进展无生存期(PFS)按青春期分期分析,CPP患者按GnRH类似物治疗与否分析。
- 采用Kaplan–Meier曲线和log-rank检验进行生存分析。
临床怎么用
- 对pLGG患儿应系统监测青春期发育,尤其下丘脑-视路受累者。
- CPP患儿可考虑GnRH类似物治疗以延长PFS,但需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pediatric low-grade gliomas (pLGGs) are the most common brain tumors in children. While overall survival is excellent, tumor progression remains frequent, especially in surgically challenging locations. Puberty brings profound hormonal changes, and growing evidence suggests that sex hormones may influence glioma biology. The impact of pubertal development, including central precocious puberty (CPP), on tumor behavior is not well understood. METHODS: We performed a retrospective study of 301 children with histologically confirmed pLGGs treated at a single tertiary center from 2015 to 2025. Data collected included clinical, radiological, endocrine, histopathological, and molecular information. Pubertal status was assessed using Tanner staging, and CPP was defined by standard clinical and hormonal criteria. Progression-free survival (PFS) was analyzed according to pubertal stage and, in patients with CPP, by treatment with gonadotropin-releasing hormone (GnRH) analogues. Kaplan–Meier curves and log-rank tests were used for survival analysis. RESULTS: Advanced pubertal development (Tanner stage > 3) was observed in 112 patients (37%), and 18 patients (6%) met criteria for CPP. Nearly all children with CPP had tumors involving the diencephalic or hypothalamic–optic pathway. Among patients with CPP, those treated with GnRH analogues (n = 13) had significantly longer PFS than untreated patients (n = 5) (p = 0.00038), with 60-month PFS of 78% versus 25%. Tumor progression after stopping GnRH therapy often coincided with pubertal reactivation. Compared with age-matched children without CPP, GnRH therapy showed a trend toward longer PFS, though not statistically significant (p = 0.10). CONCLUSIONS: Pubertal development and CPP are strongly associated with hypothalamic–optic pathway pLGGs and may influence tumor behavior in a subset of patients. In children with CPP, hormonal suppression with GnRH analogues was associated with prolonged PFS, supporting a potential modulatory role of endocrine signaling in pLGGs. These findings underscore the importance of systematic monitoring of pubertal development and warrant prospective studies to clarify the role of endocrine modulation within multimodal treatment strategies for pediatric low-grade glioma.
引用
- D'Antonio F, Rossi S, Carai A, et al. Pubertal development and hormonal modulation in pediatric low-grade gliomas: a retrospective cohort study. J Neurooncol. 2026. PMID: 41961358. doi:10.1007/s11060-026-05522-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。